Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$18.56 USD
+0.17 (0.92%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $18.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.56 USD
+0.17 (0.92%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $18.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Zacks News
J&J Files NDA for Multiple Sclerosis Drug Ponesimod in U.S.
by Zacks Equity Research
Johnson & Johnson's (JNJ) ponesimod's regulatory application in U.S is based on data from the head-to-head OPTIMUM phase III study, comparing it to Sanofi's MS drug, Aubagio.
Mallinckrodt Up on New York's Support for Opioid Settlement
by Zacks Equity Research
Mallinckrodt's (MNK) proposed global opioid settlement receives support from New York State Attorney General, taking the total support count to 48 states and territories.
J&J Files MAA for Multiple Sclerosis Drug Ponesimod in Europe
by Zacks Equity Research
Ponesimod's regulatory application in Europe is based on data from the head-to-head OPTIMUM phase III study comparing it to Sanofi's (SNY) MS drug, Aubagio
Endo's (ENDP) Earnings & Revenues Trump Estimates in Q4
by Zacks Equity Research
Endo (ENDP) earnings and sales beat estimates in the fourth quarter but witness year-over-year declines.
Momenta's (MNTA) Q4 Loss Wider than Expected, Sales Beat
by Zacks Equity Research
Momenta (MNTA) reports mixed Q4 results, with a wider-than-expected loss and revenues beating the same.
Mallinckrodt Gains on Opioid Settlement, Beats on Q4 Earnings
by Zacks Equity Research
Mallinckrodt (MNK) signs a $1.6-billion agreement for its ongoing opioid litigation and reports better-than-expected Q4 results.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries
Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates
by Zacks Equity Research
Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.
3 Best Drugmakers That Are Immune to Coronavirus Fright
by Manaswita Ghosh Dutta
The global reliance on China for APIs and drug manufacturing might hit supply chains and production amid the Coronavirus outbreak. Thus, companies independent of China's input are up for grabs now.
Teva (TEVA) Q4 Earnings In Line, Stock Up as Sales Stabilize
by Zacks Equity Research
Teva Pharmaceutical (TEVA) earnings match estimates but sales beat. Shares rise 9%.
Teva (TEVA) Q4 Earnings In Line, Sales Beat, Stock Up
by Zacks Equity Research
Teva Pharmaceutical (TEVA) matches earnings estimates but beats the same for sales. Shares rise in pre-market trading.
Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $12.10, moving +0.33% from the previous trading session.
Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal
by Zacks Equity Research
Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.
Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up
by Zacks Equity Research
Eli Lilly's (LLY) Q4 earnings and sales beat estimates. Shares rise in pre-market trading.
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)
by Zacks Equity Research
Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258
by Zacks Equity Research
Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short
by Zacks Equity Research
J&J (JNJ) comes up with mixed fourth-quarter 2019 results.
Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe
by Zacks Equity Research
Novartis' (NVS) MS drug, Mayzent, obtains approval in Europe for the treatment of adult patients with secondary progressive multiple sclerosis.
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe
by Zacks Equity Research
Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.
J&J's $8B Jury Award in Risperdal Case Cut to $6.8M by Judge
by Zacks Equity Research
A Philadelphia judge slashes J&J's (JNJ) punitive damages in a lawsuit, which claims that the company did not warm men that they could grow breasts by using its antipsychotic drug, Risperdal.
Endo Up on Opioid Abuse Settlement Agreement With Oklahoma
by Zacks Equity Research
Endo (ENDP) settles an ongoing opioid-abuse litigation issue with the state of Oklahoma for $8.75 million.
Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study
by Zacks Equity Research
Axsome's (AXSM) migraine drug meets two regulatory, co-primary endpoints in a phase III study.
Will J&J be Able to Overcome Its Legal Troubles in 2020?
by Indrajit Bandyopadhyay
Here we discuss the growth potential of J&J's (JNJ) stock in 2020.
Is Mylan (MYL) Doomed to Witness a Terrible 2020 Too?
by Zacks Equity Research
As Mylan (MYL) remained plagued with challenges in 2019, we take an insight into whether or not, the next year holds any promise for the company.